An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus
- PMID: 10694292
An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus
Abstract
Pemphigus foliaceus (PF) is an autoimmune skin disease in which loss of adhesion between keratinocytes (i.e., acantholysis) in the granular cell layers appears to be mediated by the binding of autoantibodies against desmoglein (Dsg) 1. Although it has been suggested that the activity of the disease is rather correlated with the titer of the antibody, there are still no precise studies on the relationships between the disease activity and the titers of autoantibody against Dsg1 by using ELISA. In this study, we performed ELISA using recombinant Dsg1 (rDsg1) as antigen on 8 patients with pemphigus foliaceus in order to examine the reliability of this test for monitoring disease severity. The resultant index values of ELISA, which were defined by the formula: (OD of tested serum - OD of negative control)/(OD of positive control - OD of negative control) X 100, ranged from 16 to 264 compared with 6.41 of cutoff index value for normal sera. A patient with an index value of 213 had severe widespread erosions with erythema and required pulse therapy of methylpredonisolone (1,000 mg/day for 3 days). A patient with an index value of 111 had a moderate severity and was successfully treated with an initial dose of 30 mg/day (0.64 mg/kg) of predonisolone. The mildest patient with an index value of 16 was controlled with only topical application of 0.05% betamethasone ointment twice a day. These results suggest that ELISA index values for rDsg1 will provide a promising tool for monitoring the disease severity and for determining the initial therapy for pemphigus foliaceus.
Similar articles
-
Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.Br J Dermatol. 2008 Apr;158(4):685-90. doi: 10.1111/j.1365-2133.2007.08416.x. Epub 2008 Jan 30. Br J Dermatol. 2008. PMID: 18241273
-
ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.Arch Dermatol. 2009 May;145(5):529-35. doi: 10.1001/archdermatol.2009.9. Arch Dermatol. 2009. PMID: 19451496
-
Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.Eur J Dermatol. 2003 Jul-Aug;13(4):377-81. Eur J Dermatol. 2003. PMID: 12948919
-
Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.Minerva Stomatol. 2007 Apr;56(4):215-23. Minerva Stomatol. 2007. PMID: 17452959 Review. English, Italian.
-
Neonatal pemphigus vulgaris.J Dermatol. 2008 Aug;35(8):529-35. doi: 10.1111/j.1346-8138.2008.00515.x. J Dermatol. 2008. PMID: 18789074 Review.
Cited by
-
Improving Treatment Outcome of Pemphigus Vulgaris on Vietnamese Patients by Using Desmoglein Elisa Test.Open Access Maced J Med Sci. 2019 Jan 22;7(2):195-197. doi: 10.3889/oamjms.2019.003. eCollection 2019 Jan 30. Open Access Maced J Med Sci. 2019. PMID: 30745956 Free PMC article.
-
Diagnosis and clinical features of pemphigus foliaceus.Dermatol Clin. 2011 Jul;29(3):405-12, viii. doi: 10.1016/j.det.2011.03.012. Dermatol Clin. 2011. PMID: 21605805 Free PMC article. Review.
-
Bullous skin diseases: classical types of autoimmune diseases.Scientifica (Cairo). 2013;2013:457982. doi: 10.1155/2013/457982. Epub 2013 Jan 8. Scientifica (Cairo). 2013. PMID: 24278779 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical